Emergent to Sell Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 M

 Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore-Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. (“Bora”, TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent’s Contract Development and Manufacturing Organization (CDMO), has clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services. Alongside the facility, approximately 350 current Emergent employees are expected to join Bora as part of the transaction.

https://www.globenewswire.com/news-release/2024/06/20/2901567/33240/en/Emergent-BioSolutions-Announces-Sale-of-Baltimore-Camden-Manufacturing-Site-to-Bora-Pharmaceuticals-for-30-Million.html